ArticleBlood advances2019

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Margherita Maffioli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.